{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:53:07Z","timestamp":1775872387958,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Ifosfamide is an alkylating agent used against a variety of pediatric solid tumors; ifosfamide-induced encephalopathy (IIE) is a potential life-threatening event that may occur within 24 to 48 hours after its administration. Hepatic bioactivation of ifosfamide is mediated by CYP3A4 and CYP2B6; their genetic polymorphisms may alter its metabolism, thereby promoting IIE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Here we report our experience of a 14-month-old baby affected by rhabdomyosarcoma of the bladder, who developed a severe neurotoxicity after the first dose of ifosfamide and successfully recovered after prompt methylene blue and thiamine administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Subsequent genetic analysis revealed homozygosis for CYP2B6 and heterozygosis for CYP3A4. We decided to switch therapy to an alternative alkylating agent such as cyclophosphamide, and he completed the treatment without any notable problems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>IIE is a rare but severe side effect of ifosfamide infusion, and clinical manifestations in children may be misunderstood. We speculate that pharmacogenetic testing may be warranted in very young children to prevent severe IIE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003183","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:00:09Z","timestamp":1773338409000},"page":"139-141","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Ifosfamide-Induced Encephalopathy in a Very Young Child With Rhabdomyosarcoma: Case Report and Literature Review"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2088-1305","authenticated-orcid":false,"given":"Roberta","family":"Koronica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"De Leonardis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariachiara","family":"Servedio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Novielli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enza","family":"Pentassuglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"R1-20260327","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1177\/10781552211005533","article-title":"Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer","volume":"27","author":"Ataseven","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"R2-20260327","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.1986.4.8.1253","article-title":"Central nervous system toxicity following the treatment of pediatric patients with ifosfamide\/mesna","volume":"4","author":"Pratt","year":"1986","journal-title":"J Clin Oncol"},{"key":"R3-20260327","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.arcped.2005.10.021","article-title":"Ifosfamide induced encephalopathy: 15 observations","volume":"13","author":"Dufour","year":"2006","journal-title":"Arch Pediatr"},{"key":"R4-20260327","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00002018-200831110-00003","article-title":"Encephalopathy after high-dose ifosfamide: a retrospective cohort study and review of the literature","volume":"31","author":"Sweiss","year":"2008","journal-title":"Drug Saf"},{"key":"R5-20260327","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0936-6555(03)00114-6","article-title":"Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy","volume":"15","author":"Turner","year":"2003","journal-title":"Clin Oncol"},{"key":"R6-20260327","first-page":"553","article-title":"Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases","volume":"30","author":"Duflot","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"R7-20260327","first-page":"CS22","article-title":"Neurotoxicity during ifosfamide treatment in children","volume":"15","author":"Di Cataldo","year":"2009","journal-title":"Med Sci Monit"},{"key":"R8-20260327","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00776-009-1431-y","article-title":"Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors","volume":"15","author":"Tajino","year":"2010","journal-title":"J Orthop Sci"},{"key":"R9-20260327","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1124\/dmd.105.004788","article-title":"Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450","volume":"33","author":"Chen","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"R10-20260327","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1634\/theoncologist.12-11-1351","article-title":"The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas","volume":"12","author":"Tascilar","year":"2007","journal-title":"Oncologist"},{"key":"R11-20260327","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clon.2006.11.003","article-title":"Ifosfamide encephalopathy","volume":"19","author":"Ajithkumar","year":"2007","journal-title":"Clin Oncol"},{"key":"R12-20260327","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s002280050102","article-title":"Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy","volume":"50","author":"K\u00fcPfer","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"R13-20260327","first-page":"4","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance","volume":"5","author":"Zanger","year":"2013","journal-title":"Front Genet"},{"key":"R14-20260327","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"Wang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"R15-20260327","first-page":"1766","article-title":"Genetic polymorphism of CYP3A4 is associated with poor response to ifosfamide treatment in children with solid embryonic tumors","volume":"17","author":"Espindola","year":"2019","journal-title":"Arch Med Sci"},{"key":"R16-20260327","doi-asserted-by":"crossref","first-page":"e27996","DOI":"10.1002\/pbc.27996","article-title":"Analysis of the clinical characteristics of pediatric patients who experience ifosfamide-induced encephalopathy","volume":"66","author":"Ide","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20260327","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1158\/0008-5472.CAN-06-1043","article-title":"Ifosfamide-induced nephrotoxicity: mechanism and prevention","volume":"66","author":"Nissim","year":"2006","journal-title":"Cancer Res"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:00:12Z","timestamp":1774602012000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003183","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"2025-07-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}